Rallybio Partners with Johnson & Johnson on Therapeutic Solutions to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Shots:
- Rallybio has partnered with J&J to develop therapeutic solutions for preventing fetal & neonatal alloimmune thrombocytopenia (FNAIT) as well as secured $6.6M equity
- Under the partnership, J&J will fund Rallybio to promote its FNAIT clinical program in conjunction with Rallybio’s current FNAIT natural history study. Rallybio is entitled to receive additional payments
- Rallybio's natural history study aims to gather dataset for HPA-1a alloimmunization frequency among populations to support RLYB212’s (human monoclonal anti-HPA-1a Ab) registration trial. RLYB212’s P-II dose confirmation trial in pregnant individuals at higher risk of alloimmunization & FNAIT is anticipated in H2’24
Ref: Rallybio | Image: Rallybio
Related News:- Rallybio Presents P-I Single Ascending Dose Results of RLYB116 for Complement-Mediated Diseases at ICW 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
